

David J Pinato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4085273/publications.pdf>

Version: 2024-02-01

190
papers

8,114
citations

71061

41
h-index

69214

77
g-index

193
all docs

193
docs citations

193
times ranked

9475
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 420-432.	0.6	8
2	Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma: a textbook outcome analysis. <i>Hpb</i> , 2022, 24, 664-671.	0.1	2
3	Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3
4	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	1.8	132
5	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
6	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
7	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
8	New Frontiers in the Medical Therapy of Hepatocellular Carcinoma. <i>Chemotherapy</i> , 2022, 67, 164-172.	0.8	10
9	Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis. <i>Journal of Clinical Oncology</i> , 2022, 40, 393-393.	0.8	5
10	Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs). <i>Journal of Clinical Oncology</i> , 2022, 40, 399-399.	0.8	1
11	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. <i>Journal of Clinical Oncology</i> , 2022, 40, e004374.		13
12	Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2078-2082.	0.8	11
13	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 253-264.	1.5	20
14	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	1.8	59
15	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
16	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114
17	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	1.7	44
18	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 + 50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7

#	ARTICLE	IF	CITATIONS
19	De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Managementâ€”Guidelines From the ILTS-SETH Consensus Conference. <i>Transplantation</i> , 2022, 106, e30-e45.	0.5	29
20	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
21	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
22	Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 681-691.	1.9	7
23	Reply. <i>Hepatology</i> , 2022, 76, E82-E83.	3.6	0
24	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	2.0	7
25	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
26	Outcome of liver cancer patients with SARSâ€”CoVâ€”2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
27	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
28	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	0.9	10
29	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26
30	Differential prognostic effect of systemic inflammation in patients with nonâ€”small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 <scp>OAK</scp> trial. <i>Cancer</i> , 2022, 128, 3067-3079.	2.0	15
31	Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. <i>European Journal of Cancer</i> , 2022, 172, 199-208.	1.3	9
32	Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 55-61.	1.4	42
33	Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2021, 111, 465-474.	1.2	15
34	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. <i>British Journal of Cancer</i> , 2021, 124, 407-413.	2.9	15
35	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	1.3	81
36	Qualification of tumour mutational burden by targeted nextâ€”generation sequencing as a biomarker in hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 192-203.	1.9	32

#	ARTICLE	IF	CITATIONS
37	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	1.4	15
38	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
39	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
40	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 445-445.	0.8	2
41	Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2964-2966.	3.2	0
42	Evaluating the impact of COVID-19 on supportive care needs, psychological distress and quality of life in UK cancer survivors and their support network. <i>European Journal of Cancer Care</i> , 2021, 30, e13442.	0.7	21
43	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
44	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
45	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 301.	1.1	42
46	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
47	Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2137.	1.7	11
48	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16526-e16526.	0.8	0
49	Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. <i>Liver Cancer</i> , 2021, 10, 240-248.	4.2	39
50	Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2643-2643.	0.8	1
51	Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4085-4085.	0.8	0
52	T-cell mediated responses against alpha-fetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients' survival. <i>Liver Cancer International</i> , 2021, 2, 7-14.	0.2	0
53	Impact of the G8 score on the outcome of a cohort of elderly patients with solid or hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12038-12038.	0.8	2
54	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1574-1574.	0.8	1

#	ARTICLE	IF	CITATIONS
55	SER-ONCOVID: Seroconversion in solid-tumor cancer patients after COVID-19 diagnosis.. Journal of Clinical Oncology, 2021, 39, 2544-2544.	0.8	0
56	PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.. Journal of Clinical Oncology, 2021, 39, e16131-e16131.	0.8	3
57	Post-progression outcomes of NSCLC patients with PD-L1 expression \geq 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. European Journal of Cancer, 2021, 148, 24-35.	1.3	19
58	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	2.6	36
59	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	1.3	24
60	The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Annals of Translational Medicine, 2021, 9, 1034-1034.	0.7	21
61	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	2.6	39
62	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. ESMO Open, 2021, 6, 100123.	2.0	10
63	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. Supportive Care in Cancer, 2021, 29, 7845-7854.	1.0	7
64	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology, 2021, 74, 483-490.	3.6	48
65	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	1.8	14
66	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	0.6	91
67	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	1.3	37
68	Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2021, 6, 515-516.	3.7	1
69	Abstract 485: Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study. , 2021, , .		2
70	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
71	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Science Translational Medicine, 2021, 13, .	5.8	19
72	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. Journal of Hepatology, 2021, 75, 177-189.	1.8	29

#	ARTICLE	IF	CITATIONS
73	Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. <i>Cancers</i> , 2021, 13, 4232.	1.7	3
74	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 887-897.	1.8	17
75	Upregulation of C/EBP β Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5961-5978.	3.2	47
76	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 1391-1399.	0.6	32
77	Mutations in circulating cell-free tumour DNA: Predictors of survival in hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 54-62.	0.2	1
78	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	1.3	25
79	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
80	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
81	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	3.4	42
82	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
83	Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 155, 315-316.	1.3	1
84	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100347.	2.6	57
85	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	1.3	42
86	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. , 2021, 9, e001519.		10
87	Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 908-910.	3.2	11
88	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	4.2	33
89	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	3.4	74
90	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73

#	ARTICLE	IF	CITATIONS
91	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	1.4	5
92	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	3.6	92
93	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. <i>Immunology</i> , 2020, 159, 167-177.	2.0	75
94	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
95	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135
96	Acceleration of interstitial lung disease induced by raltitrexed. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1241-1243.	0.5	1
97	Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>Journal of Immunotherapy</i> , 2020, 43, 53-56.	1.2	2
98	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3323.	1.0	131
99	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
100	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841.	1.7	58
101	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	1.7	47
102	Regorafenib therapy for hepatocellular carcinoma in a HIV-1-infected patient: A case report. <i>Liver Cancer International</i> , 2020, 1, 51-54.	0.2	2
103	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. <i>Cancers</i> , 2020, 12, 3370.	1.7	28
104	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
105	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
106	Shifting paradigms in the systemic management of hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 883-885.	3.7	1
107	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
108	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP- β , in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3936-3946.	3.2	86

#	ARTICLE	IF	CITATIONS
109	Management of Hepatocellular Cancer in the time of SARS-CoV-2. <i>Liver International</i> , 2020, 40, 1823-1825.	1.9	11
110	Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 207-208.	0.9	1
111	Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using ¹⁸ F-Fluorothymidine PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1743-1748.	2.8	9
112	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	2.6	154
113	A pathway towards precision: Setting the agenda for <i>Liver Cancer International</i> . <i>Liver Cancer International</i> , 2020, 1, 5-5.	0.2	1
114	Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 587.	3.4	2
115	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
116	Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4585-4585.	0.8	8
117	An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12049-12049.	0.8	0
118	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4601-4601.	0.8	1
119	PD-L1 status and efficacy of immune check-point inhibitors (ICIs) in advanced cancer patients: A pooled analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15263-e15263.	0.8	0
120	Post-registration experience of nivolumab (nivo) therapy in patients with advanced hepatocellular carcinoma (HCC): An international study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16677-e16677.	0.8	1
121	Influence of antibiotic therapy (ATB) on oncological outcomes of metastatic non-small cell lung cancer (mNSCLC) patients treated with chemo-immunotherapy (CIT).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3080-3080.	0.8	0
122	Retinoic Acid Receptor α 2 Is Downregulated in Hepatocellular Carcinoma and Cirrhosis and Its Expression Inhibits Myosin-Driven Activation and Durotaxis in Hepatic Stellate Cells. <i>Hepatology</i> , 2019, 69, 785-802.	3.6	50
123	The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2008-2023.	1.9	56
124	Antibiotic therapy and outcome from immune-checkpoint inhibitors. , 2019, 7, 287.		77
125	Therapeutic hierarchy in hepatocellular carcinoma: A dispute of evidence versus practice. <i>Liver International</i> , 2019, 39, 1622-1623.	1.9	1
126	Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1774.	3.4	396

#	ARTICLE	IF	CITATIONS
127	Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2019, 116, 56-66.	1.3	48
128	Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. <i>British Journal of Cancer</i> , 2019, 120, 1033-1036.	2.9	66
129	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	0.8	36
130	PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity. <i>Immunotherapy</i> , 2019, 11, 585-590.	1.0	6
131	Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 512-521.	2.9	31
132	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. <i>Liver Cancer</i> , 2019, 8, 281-294.	4.2	31
133	Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 2258-2270.	3.6	64
134	Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 211.	1.1	8
135	Editorial: a step forward in refining prognostication for patients with HIV-associated hepatocellular carcinoma—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 134-135.	1.9	0
136	Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma. <i>Medical Oncology</i> , 2018, 35, 53.	1.2	11
137	The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 95-103.	1.9	20
138	Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 139-140.	0.5	0
139	Breaking Kuhn's paradigm in advanced hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 1663-1665.	3.6	6
140	PD-L1. <i>Journal of Clinical Pathology</i> , 2018, 71, 189-194.	1.0	218
141	Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 4635-4638.	2.6	3
142	Functional immune characterization of HIV-associated non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1486-1488.	0.6	10
143	The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 714-722.	1.9	37
144	On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1146-1155.	1.9	47

#	ARTICLE	IF	CITATIONS
145	Review article: delivering precision oncology in intermediate-stage liver cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1514-1523.	1.9	30
146	Hepatocellular carcinoma. <i>Aids</i> , 2017, 31, 603-611.	1.0	30
147	Reply to: "Validating the ALBI grade: Its current and future use in HCC prognostication". <i>Journal of Hepatology</i> , 2017, 66, 663-664.	1.8	1
148	Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma. <i>Oncology</i> , 2017, 93, 395-400.	0.9	11
149	Programmed cell death ligands expression in pheochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior. <i>Oncolmmunology</i> , 2017, 6, e1358332.	2.1	60
150	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 338-346.	1.8	299
151	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. <i>Liver Cancer</i> , 2017, 6, 313-324.	4.2	21
152	Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. <i>Oncotarget</i> , 2017, 8, 36161-36170.	0.8	44
153	Gene of the month: <i>Axl</i> . <i>Journal of Clinical Pathology</i> , 2016, 69, 391-397.	1.0	30
154	Peptide receptor radionuclide therapy for metastatic paragangliomas. <i>Medical Oncology</i> , 2016, 33, 47.	1.2	44
155	Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. <i>Medical Oncology</i> , 2016, 33, 114.	1.2	4
156	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1213934.	2.1	65
157	TAMing resistance to multi-targeted kinase inhibitors through <i>Axl</i> and <i>Met</i> inhibition. <i>Oncogene</i> , 2016, 35, 2684-2686.	2.6	16
158	Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15658-e15658.	0.8	3
159	Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. <i>Oncotarget</i> , 2016, 7, 44705-44718.	0.8	32
160	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer (LC): Implications for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11601-11601.	0.8	1
161	The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. <i>Liver International</i> , 2015, 35, 2458-2465.	1.9	5
162	Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1204-1208.e2.	2.4	53

#	ARTICLE	IF	CITATIONS
163	Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 488-494.	0.4	30
164	Editorial: dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1218-1219.	1.9	0
165	Pharmacological inhibition of Axl tyrosine kinase as a novel therapeutic strategy in hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15152-e15152.	0.8	1
166	Prognostic subclassification of Intermediate Hepatocellular Carcinoma (I-HCC): a multicentre cohort study with propensity score analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15139-e15139.	0.8	0
167	Inflammation as a validated prognostic determinant in carcinoma of unknown primary site. <i>British Journal of Cancer</i> , 2014, 110, 208-213.	2.9	21
168	An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. <i>British Journal of Cancer</i> , 2014, 110, 115-122.	2.9	46
169	Cancer-related inflammation: An emerging prognostic domain in metastatic castration-resistant prostate carcinoma. <i>Cancer</i> , 2014, 120, 3272-3274.	2.0	6
170	Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1270-1281.	1.9	30
171	An Unexpected Cause of Pulmonary Cannonball Lesion. <i>Journal of Thoracic Oncology</i> , 2014, 9, 259.	0.5	2
172	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5908-5917.	3.2	38
173	Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma. <i>Advances in Anatomic Pathology</i> , 2014, 21, 270-284.	2.4	21
174	Alterations of Choline Phospholipid Metabolism in Endometrial Cancer Are Caused by Choline Kinase Alpha Overexpression and a Hyperactivated Deacylation Pathway. <i>Cancer Research</i> , 2014, 74, 6867-6877.	0.4	87
175	Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. <i>British Journal of Cancer</i> , 2014, 110, 1930-1935.	2.9	139
176	An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials. <i>PLoS ONE</i> , 2014, 9, e83279.	1.1	25
177	CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2013, 66, 256-259.	1.0	5
178	Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. <i>Cancer Treatment Reviews</i> , 2013, 39, 153-160.	3.4	53
179	The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2013, 108, 621-628.	2.9	37
180	Immunohistochemical markers of the hypoxic response can identify malignancy in pheochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. <i>British Journal of Cancer</i> , 2013, 108, 429-437.	2.9	40

#	ARTICLE	IF	CITATIONS
181	Advanced age influences the dynamic changes in circulating C-reactive protein following injury. <i>Journal of Clinical Pathology</i> , 2013, 66, 695-699.	1.0	12
182	Imatinib induced pyoderma gangrenosum. <i>Journal of Postgraduate Medicine</i> , 2013, 59, 244-245.	0.2	14
183	A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). <i>British Journal of Cancer</i> , 2012, 106, 1439-1445.	2.9	322
184	A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers. <i>PLoS ONE</i> , 2012, 7, e51395.	1.1	102
185	Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 587-594.	0.5	128
186	An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. <i>Translational Research</i> , 2012, 160, 146-152.	2.2	59
187	A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). <i>Journal of Hepatology</i> , 2012, 57, 1013-1020.	1.8	164
188	Hepatitis B virus and lymphomagenesis: Novel insights into an occult relationship. <i>Digestive and Liver Disease</i> , 2012, 44, 235-238.	0.4	5
189	Clinical, Ethical and Financial Implications of Incidental Imaging Findings: Experience from a Phase I Trial in Healthy Elderly Volunteers. <i>PLoS ONE</i> , 2012, 7, e49814.	1.1	11
190	Development and validation of a therapy-independent hepatocellular carcinoma survival prediction score. <i>Liver Cancer International</i> , 0, , .	0.2	2